Abstract. Infection with Japanese encephalitis virus (JEV) is a major public health problem in Asia. Detection of JEVspecific IgM in serum and cerebrospinal fluid (CSF) by the IgM antibody capture enzyme-linked immunosorbent assay (MAC-ELISA) is currently the most widely used diagnostic method to detect JEV infection. Because of the possible presence of IgM cross-reactivity with other flaviviruses in serum and the high ratio of inapparent-to-apparent JEV infections, a positive result in serum only suggests a recent infection and not necessarily an encephalitic illness caused by JEV. Consequently, detection of JEV-specific IgM in CSF assumes great diagnostic relevance. We evaluated two commercial JEV MAC-ELISA kits using 60 CSF samples obtained from patients with acute encephalitis syndrome. The Panbio and XCyton kits had sensitivities of 65-80% and 95% and specificities of 90% and 97.5%, respectively. Performance information on these commercial JEV MAC-ELISA kits for CSF should assist in laboratory-based JE surveillance programs.
INTRODUCTION
Japanese encephalitis virus (JEV) infection is a major public health problem in Asia. Because the clinical signs and symptoms of JE resemble several other common infections of the human nervous system such as cerebral malaria and tuberculous meningitis, and conditions such as Reye's syndrome, it is necessary to confirm the diagnosis by an appropriate laboratory test. 1 The five World Health Organization (WHO) criteria for laboratory diagnosis of JEV infection include 1) presence of IgM to JEV in cerebrospinal fluid (CSF) or serum; 2) JEV antigen detection in tissues by immunohistochemical analysis; 3) detection of JEV genomic RNA in any sample by nucleic acid detection assays; 4) virus isolation from any sample type; or 5) detection of a four-fold change in titer between serologic specimens obtained during acute and convalescent phases of illness as measured by hemagglutination inhibition assay or JEV-specific neutralizing antibody titer as determined by plaque reduction neutralization test (PRNT). 2, 3 Among these five methods, detection of JEV-specific IgM in serum and/or CSF is currently the most widely used.
The presence of IgM in serum to other flavivirus infections, which may not be the cause of the encephalitis, is problematic for JEV diagnosis in areas of Southeast Asia where cocirculation of dengue virus (DENV), West Nile virus, and JEV occurs. 4, 5 This finding limits the use of serum-based diagnostic assays in a surveillance system. Nevertheless, Jacobson and others recently evaluated three commercial kits for their sensitivity and specificity in the detection of JEV IgM in serum using the U.S. Armed Forces Research Institute of Medical Sciences in-house JEV IgM antibody capture enzyme-linked immunosorbent assay (MAC-ELISA) as a reference. 6 Although sensitivity of the three kits (manufactured by Panbio Ltd., Sinnamon Park, Queensland, Australia; Inbios International Inc., Seattle, WA; and XCyton Diagnostics Ltd., Bangalore, India) was good (89-99.2%), their specificities were variable (56.1-99.2%). However, all three kits showed a specificity > 96% when DENV IgM cross-reactivity to JEV was not considered. Other limitations with serum-based IgM detection are the high ratio of inapparent-to-apparent infections noted in JEV infection and IgM persistence in serum after JEV vaccination. 7, 8 Therefore, a positive result for serum only suggests a recent infection and not necessarily an encephalitic illness caused by JEV infection. Consequently, detection of JEV-specific IgM in a single specimen of CSF assumes great diagnostic relevance in patients with acute encephalitis syndrome (AES).
Because none of the available commercial JEV MAC-ELISA kits have been evaluated using well-characterized CSF samples, this study was designed to compare two commercial JEV MAC-ELISA kits, JE-DEN IgM Combo ELISA (Inverness Medical Innovations Ltd., Australia [formerly Panbio Ltd.]) and JEV CheX (XCyton Diagnostics Ltd.), for their sensitivity, specificity, and diagnostic utility.
MATERIALS AND METHODS

Samples.
A panel of CSF samples without personal identifiers were selected from the Department of Neurovirology, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India, collection of archived samples. The panel was comprised of 60 CSF samples: 20 samples positive for JEV IgM, which were collected from AES patients during a 2005 outbreak of JE in Assam State in northeastern India; 20 samples negative for JEV IgM, which were collected from AES patients that were investigated at NIMHANS Hospital during 2005; and 20 control samples obtained from 10 confirmed patients each with herpes simplex encephalitis and subacute sclerosing panencephalitis.
All samples were initially characterized at NIMHANS by an in-house JEV MAC-ELISA, 9 with a subset tested by a herpes simplex IgG ELISA, 10 and a measles IgG ELISA. 11 The samples were numerically coded at NIMHANS by one of the investigators (AD), and the personnel testing the samples in this evaluation were blind to the codes ( Table 1 ) . Samples were stored at −70°C.
Test methods. Two investigators (JSR and BJR) performed all evaluations in the three assays using written standard operating procedures and were blinded to the codes of the samples. All testing was completed between October 2006 and May 2007.
CDC JEV and DENV MAC-ELISA. The Centers for Disease Control and Prevention (CDC) MAC-ELISA protocol for differential diagnosis, in which the JEV and DENV MAC-ELISAs were carried out simultaneously on each CSF specimen, has been described. 12, 13 Cerebrospinal fluid is tested at the highest concentration possible in the MAC-ELISA at CDC. In this evaluation, because of the limited specimen volume and the number of tests needed to be done, CSF specimens were diluted 1:10 in the CDC JEV and DENV MAC-ELISA, consistent with the Panbio and XCyton kits. The DENV and JEV antigens from stably transformed COS-1 cells that secrete JE-or DEN virus-like particles into the supernatant were used in the CDC MACELISAs. [14] [15] [16] [17] Using tetramethylbenzidine as the substrate, we determined the positive-to-negative absorbance ratios (P/Ns) by dividing the absorbance at 450 nm (A 450 ) of the CSF specimen tested with positive antigen by the average of the A 450 of the normal control CSF tested with viral antigen. A P/N ≥ 3 was considered positive, ≥ 2 but < 3 equivocal, and < 2 negative. 12, 13, 18 Classification of specimens with both JEV and DENV IgM-positive results was resolved by differential PRNT, as described below.
CDC plaque reduction neutralization assay. Virus-specific neutralizing antibody titer in the CSF was determined by a 90% endpoint PRNT in Vero cells using a 0.5% agarose double overlay and visualized with neutral red staining in the second overlay. 19, 20 Each sample was tested simultaneously with challenge viruses ChimeriVax™-JEV and ChimeriVax™-DENV2 (Sanofi-Pasteur, Lyon, France [formerly Acambis Inc., Cambridge, MA]). [21] [22] [23] [24] The DENV2 New Guinea C (NGC) strain is the prototype virus used in the DENV2 PRNT and the parental virus to Chimerivax™-DENV2. In clinical specimens from patients infected with other DENV serotypes, there is detect able antibody cross-reactivity to DENV2 NGC and ChimeriVax™-DENV2 sufficient for initial PRNT screening (Kosoy O, CDC, unpublished data). The DENV serotype then can be identified by PRNT with each of the prototype DENV serotypes as challenge viruses. For the purposes of this study, only the initial screening DENV PRNT was performed. Each test run was validated with a standardized virus-specific mouse hyperimmune ascitic fluid positive control compared against the virus back titration. Initial dilution and lower limit of quantification was 1:4. Samples were tested simultaneously to JEV and DENV. Neutralizing antibody titer is expressed as the end-point dilution that reduced the challenge virus plaque count by 90%, based on the back titration. A ≥ 4-fold neutralizing titer difference between antibody to either DENV or JEV and antibody to the other virus indicated a virus-specific antibody response. 20, 25 CDC testing algorithm. Results of the CDC MAC-ELISA were categorized as JE positive, DEN positive, JE/DEN positive, and negative. The PRNT was performed on the samples that yielded results that were not in agreement with any of the four MAC-ELISAs (NIMHANS, Panbio, XCyton, and CDC), or in which the CDC MAC-ELISA results were both JEV and DENV IgM positive or equivocal, or in which one result was equivocal. 26 A positive or equivocal CDC MAC-ELISA result, which indicated a recent infection, together with confirmation by PRNT, with a virus-specific neutralizing antibody titer ≥ 1:4 and ≥ 4-fold than the titer to the other virus tested was considered positive; a positive or equivocal CDC MAC-ELISA result with a virus-specific neutralizing titer ≥ 1:4 but which was not 4-fold higher than the titer to the 27 For analysis, presumptive results were classified as positive results.
Panbio JE-DEN IgM Combination ELISA. The capture ELISA was performed according to manufacturer's instructions. The Panbio kit requires each sample to be tested with JEV and DENV antigens in parallel and Panbio units were calculated for both antigens; a two-step algorithm is used to interpret the results. Panbio units < 9 for JE or DEN are classified as negative, 9-11 as equivocal, and > 11 as positive. If both JE and DEN results are positive, a ratio is implemented, with JE/DEN Panbio units > 1 interpreted as presumptive JEV infection and JE/DEN Panbio units < 1 interpreted as presumptive DENV infection. There was no recommended working dilution for CSF in the kit insert. The CSF was diluted 1:10 in the evaluation based on a preliminary testing and recommendation by the manufacturer (Haffner G, Panbio Ltd., unpublished data). The Panbio interpretation for equivocal results states that samples should be re-tested and results should be confirmed by PRNT or current CDC guidelines. However, most laboratories using the kits would not have the ability to confirm the results by PRNT and would need to make an interpretation based on one replicate of ELISA results only. Therefore, for this analysis, equivocal results were classified as negative.
Because the Panbio kit was not designed for testing CSF specimens, modifications were made to the Panbio cutoff calculations and interpretations as per the manufacturer's recommendations during the evaluation (Haffner G, Panbio Ltd., unpublished data). The revised cutoff calculation for CSF for this evaluation exclusively is as follows: JE Panbio units < 2 = JE negative, 2-4 = JE equivocal, > 4 = JE positive; DEN Panbio units < 12 = DEN negative, 12-14 = DEN equivocal, > 14 = DEN positive. If JE and DEN Panbio units are positive, the sample is classified as a presumptive DENV infection. Equivocal results are also coded negative in this revised interpretation.
XCyton JEV CheX. The assay is recommended for use with serum and CSF specimens. It was performed according to the kit instructions wherein CSF samples were tested at a 1:10 dilution as described. 9 Samples with JEV CheX ELISA units < 30 are interpreted as negative, 30-99 are classified as suspected recent flavivirus infection, and ≥ 100 are considered positive for JEV infection. Statistical methods. The CDC test results were considered JE positive or JE negative. Panbio DEN-positive and negative results and XCyton flavivirus-positive and negative results were coded as JE negative. Sensitivity was defined as the percentage of CDC JEV infection positive results that had a JE-positive test kit result. Specificity was defined as the percentage of CDC JEV infection negative results that had a JE-negative kit result. Ninety-five percent confidence intervals (CIs) were calculated for sensitivity and specificity measures.
RESULTS
Clinical details of the 60 AES cases from which samples were collected for the study are summarized in Table 1 . Details of the results, which were based on the CDC testing algorithm, are shown in Table 2 . Of the 21 samples with CDC JEV IgM-positive results, 4 were confirmed as JE positive by PRNT; 16 were classified as JE presumptive, and one that was JEV and DENV IgM positive was classified as undetermined flavivirus (JE negative) based on PRNT results ( Table 2 , sample 28). Of the 16 CDC JE presumptive specimens, PRNT was not conducted for 3 because there was not enough sample volume to do the test with a 1:4 dilution and there was 100% agreement between all the assays; 8 had low positive JEV-specific neutralizing antibody titers, which were less than 4-fold greater than the titers to DENV, which were all negative; and 5 had no detectable neutralizing activity against either JEV or DENV ( Table 2 ). The classification of specimen 28, with CDC JEV and DENV IgM-positive results could not be resolved by PRNT because there was no detectable neutralizing titer to either JEV or DENV; this specimen was therefore classified as acute flavivirus infection (JE negative). Of the 40 samples CDC classified as JEV IgM-negative, no PRNT was conducted for 6 because of depletion of the sample, there was 100% agreement between the assays, and because in the CDC protocol PRNT is not conducted on samples with IgM-negative results; 32 had no detectable neutralizing activity to either JEV or DENV; 1 had a 1:4 JEV-specific titer and no titer to DENV (sample 8); and 1 had a 1:8 DENV-specific titer and no titer to JEV (sample 24). None of the 60 specimens had neutralizing antibody reactivity to both JEV and DENV.
Panbio results were analyzed with the two different interpretations, as shown in Tables 2 and 3 . The Panbio kit had sensitivities of 65-80% with the original and revised interpretations, respectively, and corresponding specificities of 95% with both interpretations. The sensitivity of the XCyton kit was 90% and the specificity was 97.5%. There was no significant difference between the performance of the two assays evaluated at the 95% CI. Overall agreement of the Panbio kit results with the CDC results was 85% and 90% in the original and revised interpretation, respectively. The agreement of XCyton kit results with the CDC results was 95%.
DISCUSSION
According to the WHO JE surveillance standards, the recommended method for confirmation of a JEV infection is detecting the presence of JEV-specific IgM in a single sample of CSF or serum. 3 Until recently, the lack of JEV MAC-ELISA commercial kit availability, especially for the detection of JEV IgM in CSF samples, resulted in several in-house assays being used for this purpose.
The major difficulty with the in-house assays has been the high variability in their performance under field conditions because of the labile nature and lack of standardization of some of the reagents and limited comparative studies of the assays. Conversely, commercial kits use stabilized reagents that enable them to be used in laboratories that may have limited ultralow temperature storage. An additional advantage in using commercial kits is that interlaboratory comparison of results is possible if the same kit is used across a region. Recently, WHO has established a network of 11 JE diagnostic laboratories in six countries of the WHO South East Asian Region. One of the objectives of this network is to provide standardized laboratory diagnostic results in the various countries in the region. This would enable interlaboratory comparison of results across the region and provide reliable information on disease burden. It is in this context that this study was conceived. Because there has been no side-by-side evaluation of commercially available JEV MAC-ELISA kits using CSF samples, we undertook this study to evaluate two commercially available JEV MAC-ELISA kits, manufactured by Panbio and XCyton, for their sensitivity and specificity against a reference standard.
The Panbio kit in its current format has been developed to be used with serum samples and has not been formally evaluated using CSF samples. The assay was therefore initially evaluated for its ability to detect JEV IgM in CSF samples as per the protocol provided by the manufacturer (Haffner G, Panbio Ltd., unpublished data). After communicating the results of a preliminary evaluation for a small set of samples, the manufacturer suggested some alterations in the cutoff for interpretation of the results (Haffner G, personal communication). As evident from the results in Table 3 , sensitivity of the Panbio kit was 65% prior to adjustment in the cutoff values. However, if the revised cutoff values were used, the sensitivity of the assay was much improved (80%). In contrast, the specificity of this kit remained high (95%) irrespective of the cutoffs used ( Table 3 ) . Panbio instructs laboratories to re-test samples that have equivocal results and to confirm results by PRNT or current CDC guidelines. Most diagnostic laboratories testing for JE do not have facilities for conducting PRNT or other tests and therefore would have to classify the sample based on Panbio kit results. In this evaluation equivocal results were coded as negative, per the CDC testing algorithm (see Materials and Methods). If the 4 samples interpreted as JE equivocal with the Panbio revised cutoff were coded as positive, the sensitivity would increase from 80% to 90% and specificity would decrease from 95% to 90%.
The XCyton kit has been developed for use with serum and CSF samples and had been evaluated with well-characterized CSF samples, but not in side-by-side comparison with other kits, as had been done with sera. 6, 9 The XCyton kit exhibited a higher sensitivity (90%) and specificity (97.5%) compared with the Panbio kit ( Table 3 ) . However, the differences were not significant at the 95% confidence level.
In patients with JE neuroinvasive disease, JEV IgM may not be present at detectable levels within the first few days of illness. However, > 90% of patients have detectable JEV IgM in CSF by 5-7 days post-onset of illness. 7 Results of NIMHANS JEV IgM detection in relation to the duration of illness in the AES cases are shown in Figure 1 . As evident from this figure, 76% (13 of 17) of the samples collected from suspected JE AES cases on or beyond the fifth day after onset of illness were positive for JEV IgM in CSF compared with 29% (6 of 21) of the samples obtained early in the illness ( P = 0.003). These samples were single specimens collected during the acute phase of AES, and without collection of convalescentphase specimens, the status of the AES patients with JEV IgM-negative results could not be determined. To characterize the types of specimens that the assays failed to detect, we compared the CDC JEV IgM-positive CSF specimens classified as negative in the Panbio (7 of 20 original and 4 of 20 revised cutoff) and XCyton (2 of 20) kits to date of CSF collection post-onset of illness. However, there was no correlation.
For surveillance and clinical case management, a high specificity is desirable in JEV IgM assays. A false-positive result in the JEV IgM assay may result in the clinician discontinuing further diagnostic testing and not considering management options for other treatable causes of AES such as cerebral malaria and tuberculous meningitis. In contrast, a clinician may still consider JEV infection based on clinical symptoms and timing of specimen collection, despite false-negative results. The Panbio and XCyton kits showed satisfactory specificity (≥ 95%) with this set of well-characterized CSF specimens.
The CSF from NIMHANS provided an ideal, albeit limited, sample set for the evaluation. The CSF specimens were collected from patients with encephalitis or meningitis clinical syndrome and thus were representative of samples that would routinely be submitted for JE serologic testing. The sample size was limited by the difficulty of obtaining CSF samples from AES cases with sufficient volume for testing across all the reference assays and kits. Because the CSF was submitted to NIMHANS for testing directly from the hospital, there was sufficient volume to carry out most of the testing for the evaluation. This is the first study to provide information on the relative performance of two commercial kits for the detection of JEV IgM in CSF. The reporting of these results, together with those from kit evaluations using specimens collected during AES surveillance projects, should give an accurate assessment of the suitability of these kits for widespread use.
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